Manager, Biostatistics
Madrigal Pharmaceuticals Inc - PA - Conshohocken - Office
Posted Oct 19, 2026
Benefits
- Parental leave
- Not verified
- Non-birth-parent leave
- Not verified
- Family-building benefits
-
- Fertility benefits: Not verified
- Adoption assistance: Not verified
- Surrogacy assistance: Not verified
- Mental health support
- Offered From the posting source checked Nov 17, 2026
- Relocation assistance
- Not verified
- Childcare support
- Not verified
- Learning budget
- Not verified
- Verification
- Not verified checked Nov 20, 2026
- Salary
- $149K-$181K From the posting source checked Nov 17, 2026
- 401(k) match
- Reported from DOL Form 5500 industry filing (not employer-specific)
Was this benefit information wrong? Tell us.
Market context
- U.S. role benchmark (BLS OEWS)
- $111,944 U.S. median for this role
- Projected growth (BLS Employment Projections)
- +13.7% - Much faster than average
U.S. benchmark only; posted salary is not compared across countries or currencies.
Matched to SOC 15-1252 - Data and ML aggregate by role bucket.
Source:U.S. Bureau of Labor Statistics, OEWS, May 2024andEmployment Projections, 2024-2034.
Role
Schedule
- Shift type
- Not verified
- Weekend work
- Not verified
Company
- Equity
- Offered Verified - SEC 10-K source checked Nov 17, 2026
Application
- Cover letter
- Not verified
- Assessment
- Not verified
- Deadline
- Not stated
Where they hire
State eligibility is not yet verified.
About this role
Manager, Biostatistics PA - Conshohocken - Office Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. The Manager, Biostatistics is an early-career individual contributor that will contribute to multiple biostatistical activities for Madrigal Pharmaceuticals, covering all phases of clinical development and post-marketing efforts. This role will support the translation of organizational objectives into statistical deliverables, contribute to the execution of statistical strategies, and deliver high-quality analytical outputs. This role will collaborate with other biostatisticians, programmers and cross-functional team members either within the company or at a CRO partner to ensure that Madrigal's analytical objectives are
Read the full description at madrigalpharma.wd501.myworkdayjobs.com. FewerJobs shows a preview and links to the original posting.
Apply link verified; last checked Nov 20, 2026.
What verified means
Verified means a displayed claim has field-level provenance to a source FewerJobs pulled: a government or employer source, or the original job posting. Posting-sourced facts are employer-stated and are labeled separately from government records.
Related jobs
Senior Director Biostatistics
Madrigal Pharmaceuticals Inc - PA - Conshohocken - Office
Director – Biostatistics
Rezolute Inc - Redwood City
Director, Biostatistics, Early Phase
Revolution Medicines - Redwood City, California, United States
Biostatistics Manager - HTA
Amgen - 6 Locations